Armistice Capital LLC Invests $944,000 in DexCom, Inc. (NASDAQ:DXCM)

Armistice Capital LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 8,328 shares of the medical device company’s stock, valued at approximately $944,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in DexCom by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after acquiring an additional 136,282 shares during the period. Capital Research Global Investors boosted its holdings in DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC grew its stake in shares of DexCom by 10.2% in the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after acquiring an additional 1,398,136 shares during the last quarter. Capital World Investors increased its holdings in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after acquiring an additional 5,256,092 shares in the last quarter. Finally, Blair William & Co. IL raised its position in shares of DexCom by 1.4% in the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock worth $628,684,000 after purchasing an additional 64,683 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. Insiders have sold a total of 1,824 shares of company stock valued at $126,390 over the last ninety days. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DXCM shares. Stifel Nicolaus raised their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. BTIG Research reduced their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Oppenheimer decreased their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Finally, Wells Fargo & Company decreased their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Six investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $112.25.

DexCom Trading Up 1.2 %

Shares of DXCM opened at $67.53 on Friday. The firm has a market capitalization of $26.86 billion, a price-to-earnings ratio of 43.57, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a 50-day moving average of $75.42 and a 200 day moving average of $108.17.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the company posted $0.34 earnings per share. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. On average, research analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.